NeuroSense announces shareholder letter availability

Reuters2026/08/13 13:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NeuroSense Therapeutics released a CEO letter to shareholders outlining near-term priorities for PrimeC in ALS.
FDA clearance received to start the Phase 3 PARAGON study; planned enrollment about 300 participants, mainly in the US.
Financing to run PARAGON has taken longer than expected; talks continue with strategic partners, investors, grants, non-dilutive sources.
Canada regulatory path pursued; New Drug Submission for PrimeC targeted for December 2026, based on Phase 2b PARADIGM data.
Nasdaq compliance efforts focus on bid-price; board authority sought for a 1-for-4 to 1-for-40 reverse split if needed.
CEO Alon Ben-Noon, CFO Or Eisenberg invested USD 200,000 each in April 2026; combined with another investor totaled USD 600,000.
https://www.neurosense-tx.com/

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NeuroSense announces shareholder letter availability

You may also like

Crypto prices